Discontinuation of anti-VEGF cancer therapy promotes metastasis through a liver revascularization mechanism
Anti-VEGF therapy often produces limited beneficial effects in cancer patients. Here, the authors show that discontinuation of anti-VEGF cancer therapy in xenografts-bearing mice increases cancer cells extravasation and intravasation in liver through the host-derived VEGF.
Guardado en:
Autores principales: | Yunlong Yang, Yin Zhang, Hideki Iwamoto, Kayoko Hosaka, Takahiro Seki, Patrik Andersson, Sharon Lim, Carina Fischer, Masaki Nakamura, Mitsuhiko Abe, Renhai Cao, Peter Vilhelm Skov, Fang Chen, Xiaoyun Chen, Yongtian Lu, Guohui Nie, Yihai Cao |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Nature Portfolio
2016
|
Materias: | |
Acceso en línea: | https://doaj.org/article/79582752f03043d7b3b6d8145bb72174 |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
MT1-MMP sheds LYVE-1 on lymphatic endothelial cells and suppresses VEGF-C production to inhibit lymphangiogenesis
por: Hoi Leong Xavier Wong, et al.
Publicado: (2016) -
Endothelial PDGF-CC regulates angiogenesis-dependent thermogenesis in beige fat
por: Takahiro Seki, et al.
Publicado: (2016) -
Therapeutic paradigm of dual targeting VEGF and PDGF for effectively treating FGF-2 off-target tumors
por: Kayoko Hosaka, et al.
Publicado: (2020) -
The PDGF-BB-SOX7 axis-modulated IL-33 in pericytes and stromal cells promotes metastasis through tumour-associated macrophages
por: Yunlong Yang, et al.
Publicado: (2016) -
Cardiovascular revascularization medicine
Publicado: (2005)